US20170266205A1 - Inducing lactation in nursing females - Google Patents
Inducing lactation in nursing females Download PDFInfo
- Publication number
- US20170266205A1 US20170266205A1 US15/479,009 US201715479009A US2017266205A1 US 20170266205 A1 US20170266205 A1 US 20170266205A1 US 201715479009 A US201715479009 A US 201715479009A US 2017266205 A1 US2017266205 A1 US 2017266205A1
- Authority
- US
- United States
- Prior art keywords
- cream
- canceled
- androgen
- stanozolol
- improvement
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000006651 lactation Effects 0.000 title claims abstract description 10
- 230000001939 inductive effect Effects 0.000 title claims 2
- 230000000474 nursing effect Effects 0.000 title description 7
- 239000006071 cream Substances 0.000 claims abstract description 39
- LKAJKIOFIWVMDJ-IYRCEVNGSA-N Stanazolol Chemical compound C([C@@H]1CC[C@H]2[C@@H]3CC[C@@]([C@]3(CC[C@@H]2[C@@]1(C)C1)C)(O)C)C2=C1C=NN2 LKAJKIOFIWVMDJ-IYRCEVNGSA-N 0.000 claims abstract description 16
- 229960000912 stanozolol Drugs 0.000 claims abstract description 16
- 229940100611 topical cream Drugs 0.000 claims abstract description 8
- 210000002445 nipple Anatomy 0.000 claims abstract description 6
- 239000003098 androgen Substances 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 6
- POZRVZJJTULAOH-LHZXLZLDSA-N danazol Chemical compound C1[C@]2(C)[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=CC2=C1C=NO2 POZRVZJJTULAOH-LHZXLZLDSA-N 0.000 claims description 5
- 229960000766 danazol Drugs 0.000 claims description 5
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims description 4
- YRCWQPVGYLYSOX-UHFFFAOYSA-N synephrine Chemical compound CNCC(O)C1=CC=C(O)C=C1 YRCWQPVGYLYSOX-UHFFFAOYSA-N 0.000 claims description 4
- PEYUIKBAABKQKQ-AFHBHXEDSA-N (+)-sesamin Chemical compound C1=C2OCOC2=CC([C@H]2OC[C@H]3[C@@H]2CO[C@@H]3C2=CC=C3OCOC3=C2)=C1 PEYUIKBAABKQKQ-AFHBHXEDSA-N 0.000 claims description 2
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims description 2
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 claims description 2
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 claims description 2
- 235000010385 ascorbyl palmitate Nutrition 0.000 claims description 2
- 229960001948 caffeine Drugs 0.000 claims description 2
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims description 2
- PEYUIKBAABKQKQ-UHFFFAOYSA-N epiasarinin Natural products C1=C2OCOC2=CC(C2OCC3C2COC3C2=CC=C3OCOC3=C2)=C1 PEYUIKBAABKQKQ-UHFFFAOYSA-N 0.000 claims description 2
- 230000003020 moisturizing effect Effects 0.000 claims description 2
- 229960001576 octopamine Drugs 0.000 claims description 2
- 229960003684 oxedrine Drugs 0.000 claims description 2
- VRMHCMWQHAXTOR-CMOCDZPBSA-N sesamin Natural products C1=C2OCOC2=CC([C@@H]2OC[C@@]3(C)[C@H](C=4C=C5OCOC5=CC=4)OC[C@]32C)=C1 VRMHCMWQHAXTOR-CMOCDZPBSA-N 0.000 claims description 2
- 229960000317 yohimbine Drugs 0.000 claims description 2
- BLGXFZZNTVWLAY-SCYLSFHTSA-N yohimbine Chemical compound C1=CC=C2C(CCN3C[C@@H]4CC[C@H](O)[C@@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-SCYLSFHTSA-N 0.000 claims description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims 1
- RGLLOUBXMOGLDQ-IVEVATEUSA-N Furazabol Chemical compound C([C@@H]1CC2)C3=NON=C3C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@](C)(O)[C@@]2(C)CC1 RGLLOUBXMOGLDQ-IVEVATEUSA-N 0.000 claims 1
- RDHQFKQIGNGIED-MRVPVSSYSA-N O-acetyl-L-carnitine Chemical compound CC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C RDHQFKQIGNGIED-MRVPVSSYSA-N 0.000 claims 1
- QHGUCRYDKWKLMG-MRVPVSSYSA-N Octopamine Natural products NC[C@@H](O)C1=CC=C(O)C=C1 QHGUCRYDKWKLMG-MRVPVSSYSA-N 0.000 claims 1
- 229950010710 furazabol Drugs 0.000 claims 1
- 229940067606 lecithin Drugs 0.000 claims 1
- 235000010445 lecithin Nutrition 0.000 claims 1
- 239000000787 lecithin Substances 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 abstract description 9
- 102400000050 Oxytocin Human genes 0.000 description 4
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 4
- 101800000989 Oxytocin Proteins 0.000 description 4
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 4
- 229960001723 oxytocin Drugs 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 108090000189 Neuropeptides Proteins 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 239000004909 Moisturizer Substances 0.000 description 1
- 102000003797 Neuropeptides Human genes 0.000 description 1
- 102000034755 Sex Hormone-Binding Globulin Human genes 0.000 description 1
- 108010089417 Sex Hormone-Binding Globulin Proteins 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- -1 danazol Chemical class 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- QHGUCRYDKWKLMG-UHFFFAOYSA-N octopamine Chemical compound NCC(O)C1=CC=C(O)C=C1 QHGUCRYDKWKLMG-UHFFFAOYSA-N 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 230000001515 vagal effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
Definitions
- the cream for the treatment of HSDD in women.
- the cream thereof is directed to causing a local physiological effect that stimulates the vagal nerves to mediate the neuropeptides that are linked to the brain for controlling oxytocin release.
- a topical cream which when applied to the nipple(s) of a nursing female, induces increased lactation.
- the cream generally, comprises: (a) a base cream having from about 0.5% to about 10%, by volume, of a steroid, based upon the total volume of the cream; and (b) preferably, at least about 1% to about 10% by volume, of the steroid, based on the total volume of the cream.
- the steroid used herein is preferably an androgen and, most preferably, stanozolol.
- the cream hereof generally, comprises: (a) a base cream having from about 0.5% to about 10%, by volume, of a steroid, based upon the total volume of the cream; and (b) preferably, from at least about 1% to about 10% by volume, of a steroid, based on the total volume of the cream.
- the steroid used herein is, preferably, an androgen and, is selected from the group consisting of, stanozolol, danazol and furazobol.
- a commercially available base cream is used.
- Commercially available base creams include emollients, water, alcohols, such as isopropyl alcohol and benzyl alcohol, glycerol, fragrances, moisturizers and the like as well as mixtures thereof.
- a particularly preferred base cream is that sold under the mark Lipoderm.
- Lipoderm is reported as having two forms, Lipoderm Ultra and Lipoderm Y, each, comprising a proprietary blend of yohimbine HCl, caffeine, synephrine, acetyl L-carntine, lechithin, sesamin, octopamine HCl and ascorbyl palmitate.
- base cream may be used alone or in admixture with other creams such as commercially available face creams, body moisturizing creams and the like, as well as mixtures thereof.
- base cream and other additional cream may be used in any amount up to about a 50:50 volumetric mixture thereof of base cream to additional cream.
- the androgen which is, preferably, stanozolol, is present in an amount ranging from about 0.5% to about 10%, by volume, based on the total volume of the topical cream. It should be noted that other steroids, such as danazol, furazobol, and the like may be used in lieu of the stanozolol, while effective, they are to a lesser degree.
- the stanozolol is used alone, although it may be used in conjunction with the danazol and/or the furazobol.
- the danazol or furazobol may be substituted for the stanozolol in the same amounts as the stanozolol.
- the stanozolol cream hereof is prepared by admixing, at room temperature, the base cream and the stanozolol. Any other ingredients or adjuvants, where used, are added thereto and stirred to form a homogenous composition.
- stanozolol releases testosterone which triggers a spinothalmic tract which, in turn, activates oxytocin related axons from the brain and, thus, serves as a neuropeptide mediator.
- the stanozolol minimizes the effect of the sex hormone binding globulin in the cell wall.
- the cream is applied to a nipple prior to breast feeding.
- the cream is left on the nipple for about five to about twenty minutes and, usually, for about five to about fifteen minutes.
- a nursing mother having a six-month old child with the ability to achieve adequate lactation has applied a 2 ml quantity of a Lubriderm Ultra cream having two percent, by volume, stanozolol added thereto.
- the so-applied cream is left on for about two minutes. It is then washed off.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A topical cream applied to a nipple of a lactating female induces lactation. The cream comprises a base cream having from about 0.5% to about 10%, by volume, of a steroid, based upon the total volume of the cream. The preferred steroid is stanozolol. Preferably, the cream comprises at least about 1% to about 10%, by volume, of stanozolol, based on the total volume of the cream.
Description
- This application is a completion application and claims the benefit of co-pending U.S. Provisional Patent Application Ser. No. 61/935,598, filed Feb. 4, 2014 for “Induction of Lactation in Nursing Females” and is related to the subject matter of co-pending U.S. patent application Ser. No. 13/745,934, filed Jan. 21, 2013, the disclosures of both are hereby incorporated by reference in their entireties.
- In the above-referenced related application there is disclosed the use of a topical cream for the treatment of HSDD in women. As disclosed, the cream thereof is directed to causing a local physiological effect that stimulates the vagal nerves to mediate the neuropeptides that are linked to the brain for controlling oxytocin release.
- It has now been found that the cream thereof generates an increase in the release of oxytocin in nursing females. The oxytocin release causes an induction of lactation.
- In accordance herewith there is provided a topical cream, which when applied to the nipple(s) of a nursing female, induces increased lactation.
- The cream, generally, comprises: (a) a base cream having from about 0.5% to about 10%, by volume, of a steroid, based upon the total volume of the cream; and (b) preferably, at least about 1% to about 10% by volume, of the steroid, based on the total volume of the cream.
- The steroid used herein is preferably an androgen and, most preferably, stanozolol.
- For a more complete understanding of the present invention, reference is made to the following detailed description and the accompanying example.
- As noted above, the cream hereof, generally, comprises: (a) a base cream having from about 0.5% to about 10%, by volume, of a steroid, based upon the total volume of the cream; and (b) preferably, from at least about 1% to about 10% by volume, of a steroid, based on the total volume of the cream.
- The steroid used herein is, preferably, an androgen and, is selected from the group consisting of, stanozolol, danazol and furazobol.
- More particularly, in preparing the topical cream hereof, a commercially available base cream is used. Commercially available base creams, as is known to the skilled artisan, include emollients, water, alcohols, such as isopropyl alcohol and benzyl alcohol, glycerol, fragrances, moisturizers and the like as well as mixtures thereof.
- A particularly preferred base cream is that sold under the mark Lipoderm. Lipoderm is reported as having two forms, Lipoderm Ultra and Lipoderm Y, each, comprising a proprietary blend of yohimbine HCl, caffeine, synephrine, acetyl L-carntine, lechithin, sesamin, octopamine HCl and ascorbyl palmitate.
- It should be noted that the base cream may be used alone or in admixture with other creams such as commercially available face creams, body moisturizing creams and the like, as well as mixtures thereof.
- Where used the base cream and other additional cream may be used in any amount up to about a 50:50 volumetric mixture thereof of base cream to additional cream.
- The androgen, which is, preferably, stanozolol, is present in an amount ranging from about 0.5% to about 10%, by volume, based on the total volume of the topical cream. It should be noted that other steroids, such as danazol, furazobol, and the like may be used in lieu of the stanozolol, while effective, they are to a lesser degree.
- Preferably, the stanozolol is used alone, although it may be used in conjunction with the danazol and/or the furazobol.
- Also, as noted above, the danazol or furazobol may be substituted for the stanozolol in the same amounts as the stanozolol.
- The stanozolol cream hereof is prepared by admixing, at room temperature, the base cream and the stanozolol. Any other ingredients or adjuvants, where used, are added thereto and stirred to form a homogenous composition.
- It is hypothesized that there is a local physiological effect whereby stanozolol releases testosterone which triggers a spinothalmic tract which, in turn, activates oxytocin related axons from the brain and, thus, serves as a neuropeptide mediator. Concomitantly the stanozolol minimizes the effect of the sex hormone binding globulin in the cell wall. These effects induce lactation when the cream is applied to a women's nipple prior to nursing.
- In use, the cream is applied to a nipple prior to breast feeding. Generally, the cream is left on the nipple for about five to about twenty minutes and, usually, for about five to about fifteen minutes.
- It is then removed by washing. Then the mother is then ready to being nursing.
- The utilization of the cream is continued, as needed, until adequate lactation is achieved.
- For a more complete understanding of the present invention reference is made to the following illustrative Example. In the Example all parts are by volume, absent indications to the contrary.
- A nursing mother having a six-month old child with the ability to achieve adequate lactation has applied a 2 ml quantity of a Lubriderm Ultra cream having two percent, by volume, stanozolol added thereto. The so-applied cream is left on for about two minutes. It is then washed off.
- Thereafter, the mother reported an increase in milk production.
- From the above, it is to be appreciated that there is described herein a topical cream which has a positive effect on women having a need to stimulate adequate lactation.
Claims (15)
1. (canceled)
2. (Canceled)
3. (Canceled)
4. (Canceled)
5. (Canceled)
6. (Canceled)
7. (Canceled)
8. (Canceled)
9. (Canceled)
10. (Canceled)
11. In a topical cream for inducing lactation in a female of the type which is applied to at least one nipple, the improvement which comprises:
an effective amount of an androgen consisting essentially of an androgen-containing topical cream, the cream comprising: (a) an androgen and a blend of yohimbine HCL, caffeine, synephrine, acetyl L-carnitine, lecithin, sesamin, octopamine HO2 and ascorbyl palmitate.
12. The improvement of claim 11 wherein the androgen is present in an amount ranging from about 1% to about 10%, by volume, based on the total volume of the cream.
13. The improvement of claim 12 which further includes an additional cream selected from the group consisting of face creams and body moisturizing creams.
14. The improvement of claim 13 wherein the androgen is selected from the group consisting of stanozolol, danazol and furazabol.
15. The improvement of claim 14 wherein the androgen is stanozolol.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15/479,009 US20170266205A1 (en) | 2014-02-04 | 2017-04-04 | Inducing lactation in nursing females |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461935598P | 2014-02-04 | 2014-02-04 | |
| US14/613,741 US9610296B2 (en) | 2013-01-21 | 2015-02-04 | Inducing lactation in nursing females |
| US15/479,009 US20170266205A1 (en) | 2014-02-04 | 2017-04-04 | Inducing lactation in nursing females |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US14/613,741 Division US9610296B2 (en) | 2012-01-19 | 2015-02-04 | Inducing lactation in nursing females |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US20170266205A1 true US20170266205A1 (en) | 2017-09-21 |
Family
ID=53753910
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US14/613,741 Expired - Fee Related US9610296B2 (en) | 2012-01-19 | 2015-02-04 | Inducing lactation in nursing females |
| US15/479,009 Abandoned US20170266205A1 (en) | 2014-02-04 | 2017-04-04 | Inducing lactation in nursing females |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US14/613,741 Expired - Fee Related US9610296B2 (en) | 2012-01-19 | 2015-02-04 | Inducing lactation in nursing females |
Country Status (1)
| Country | Link |
|---|---|
| US (2) | US9610296B2 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016201286A1 (en) * | 2015-06-11 | 2016-12-15 | Applied Biology, Inc. | Treatment of sexual dysfunction |
| CN112999156B (en) * | 2021-03-03 | 2023-09-08 | 宁波御坊堂生物科技有限公司 | Erection-assisting time-delay essential oil spray with synergistic yohimbine hydrochloride and preparation method thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2589898A (en) * | 1948-04-03 | 1952-03-18 | American Dairies Inc | Method of stimulating the growth of mammary glands and lobulealveolar system of mammals |
| WO1998008547A1 (en) * | 1996-08-29 | 1998-03-05 | Sekisui Kagaku Kogyo Kabushiki Kaisha | Stanozolol-containing percutaneously absorbable preparation |
| US20070207197A1 (en) * | 2006-02-13 | 2007-09-06 | Villarreal J A | Composition and method for reducing symptoms of breast engorgement |
| US20090202645A1 (en) * | 2008-02-08 | 2009-08-13 | Acme Drugs S.R.L. | Intrasynovial formulations of stanozolol |
-
2015
- 2015-02-04 US US14/613,741 patent/US9610296B2/en not_active Expired - Fee Related
-
2017
- 2017-04-04 US US15/479,009 patent/US20170266205A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US9610296B2 (en) | 2017-04-04 |
| US20150216880A1 (en) | 2015-08-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11026987B2 (en) | Composition for remedying female climacteric syndrome symptoms | |
| EP2844219B1 (en) | Sensitization composition and method of use | |
| US9610296B2 (en) | Inducing lactation in nursing females | |
| Hroshovyi et al. | DRONE BROOD–AS A RAW MATERIAL FOR THE MANUFACTURE OF MEDICINES AND DIETARY SUPPLEMENTS. | |
| US20210213085A1 (en) | Pharmaceutical Composition for Preventing or Treating Muscle Diseases, Containing Ginseng Berry Extract as Active Ingredient | |
| JP5153948B1 (en) | Allergic rhinitis coating agent | |
| CN104784223A (en) | Composition with itching removing function and preparation method thereof | |
| CN101366927B (en) | honey gastrodia ointment | |
| CN105963350A (en) | A natural vitamin e soft capsule | |
| CN103690454A (en) | Traditional Chinese medicinal shower gel | |
| KR101965849B1 (en) | Composition for relieving menopausal symptom comprising Tectorigenin 7-O-xylosylglucoside | |
| JP2013536169A5 (en) | ||
| Siuko et al. | Effect of the hydrocortisone on the formation of collagen in guinea pig skin | |
| KR102081003B1 (en) | Composition comprising suberic acid for preventing hair loss or stimulating hair growth | |
| WO2016111477A1 (en) | Cosmetic composition for alleviation or improvement of sebum secretion stimulated by stress, comprising, as active ingredient, extract of carthamus tinctorious l. seed, or mixed extract of carthamus tinctorious l. seed and areca catechu l. seed | |
| JP6484547B2 (en) | Pruritus improving agent | |
| KR101742819B1 (en) | Medicinal herb extract for growing or restoring hair and cosmetic composition comprising the same | |
| CN104188824A (en) | Bath cream for pet and preparation method of bath cream | |
| KR20160008282A (en) | Vitamin C Composition with Improved Absorption Rate and the Method thereof (2) | |
| JP2014522848A5 (en) | ||
| CN105368608A (en) | Folium artemisiae argyi wax handmade soap and preparation method thereof | |
| KR20160008275A (en) | Vitamin C Composition with Improved Absorption Rate and the Method thereof (1) | |
| TWI640326B (en) | Use of an extract of cocoa rind | |
| JP2003530324A (en) | Hop and Ornithine Beauty Use | |
| WO2023076219A3 (en) | Antagonists of gpr39 protein |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |